The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

India, June 14 -- Researchers at Amsterdam UMC, working alongside several partner hospitals, have completed the world's first ...

Researchers from Skoltech—a VEB.RF group institution—and their colleagues from the U.S. and China have explained how the ...

Phase III trial shows majority of patients become attack-free without ongoing meds ...

Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first Phase III study of an in vivo CRISPR therapy. In this large-scale, double-blind trial, 80 ...

For years, CRISPR Therapeutics (CRSP 1.25%) has been the type of stock investors might call a home run swing. The company ...

With an analyst consensus upside of 52.3%, CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the under-the-radar stocks with ...

CRISPR Therapeutics (NasdaqGM:CRSP) filed a large shelf registration, creating capacity to issue new securities over time.

Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first-ever Phase 3 ...

View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.

2023 was the year that CRISPR gene-editing sliced its way out of the lab and into the public consciousness—and American medical system. The Food and Drug Administration recently approved the first ...

Eight years after a Chinese scientist's report of gene-edited babies shocked the world, U.S. scientists reported editing ...